Geoffrey M. Lynn, MD, PhD, is a biotech innovator and executive with experience spanning multiple therapeutic modalities and disease areas. He founded and served as CEO of Avidea Technologies, leading the company from its inception at Johns Hopkins FastForward through its acquisition by Vaccitech (now Barinthus Biotherapeutics), where he became Chief Scientific Officer and helped guide scientific and corporate strategy. After supporting Barinthus’ merger with Clywedog Therapeutics, he joined Blackbird Labs as an Entrepreneur-in-Residence and now serves as the founding CEO of Aletira Therapeutics, which is leveraging advances in alternative splicing biology to build a pipeline of gene therapies. Dr. Lynn trained as a postdoctoral fellow with Robert Seder at the NIH, earned his MD from Johns Hopkins, and completed his PhD in Biomedical Engineering at the University of Oxford as an NIH-Oxford-Cambridge Scholar and NSF Graduate Research Fellow. He received his BS in chemistry from Elon University where he was a Goldwater Scholar.